In exchange for voluntarily selling their medications for less the companies agreed to a three-year grace period during which their products won’t face Trump’s planned pharmaceutical-specific tariffs – as long as the drugmakers further invest in U.S. manufacturing.

In July Trump sent 17 drug manufactures letters over their pricing and Eli Lilly, Novo Nordisk, Pfizer, AstraZeneca and EMD Serono reached agreements with the Admin. Now Merck, Bristol Myers Squibb, Amgen, Gilead, GSK, Sanofi, Roche’s Genentech, privately-held Boehringer Ingelheim and Novartis have reached agreements. That leaves 3 that have not reached an agreements in Johnson & Johnson, AbbVie and Regeneron.

Americans are just plain getting ripped on drug prices compared to the rest of the world.

U.S. prescription drug prices on average are nearly three times higher than overseas, according to a 2024 study by RAND Corporation. Prices for branded drugs were more than four times higher, the report found.

Its time for this to be addressed and stopped esp. given how much they rely on the US markets to make money.